Ellie’s Law

Ellie's Law (HR2678) was introduced on April 7, 2025, and referred to the House Committee on Energy and Commerce. The bill directs the National Institute of Neurological Disorders and Stroke (NINDS) to conduct and support comprehensive research on unruptured intracranial aneurysms, develop diagnostics and treatments, and create a public education campaign. Critically, the bill authorizes no specific dollar amount — it is a policy authorization that sets a program in law but requires a separate appropriations bill to allocate any actual funds. With 46 bipartisan cosponsors and a companion bill (S1609) in the Senate, momentum is building, but the bill remains at the very earliest legislative stage with no committee hearings or markups yet scheduled. The money trail is zero. Authorization bills set policy ceilings but do not allocate money. Actual funding for NINDS aneurysm research would require a future appropriations bill — and even then, the amount is unspecified. The structural impact on the medical device and diagnostics sectors is purely directional and long-dated: if future appropriations materialize, NINDS could award research grants that accelerate development of neurovascular devices (MDT's flow diverters, coils) and diagnostic tools (ILMN sequencing for genetic risk, TMO research equipment, DGX lab testing). But no contracts or revenues are guaranteed by this bill. Market data as of April 30, 2026 shows MDT at $79.22 (down 8.57% in 30 days, approaching 52-week low of $78.91), ISRG at $449.95 (down 2.39% in 30 days), TMO at $469.51 (down 4.48% in 30 days), ILMN at $123.58 (up 0.26% in 30 days), and DGX at $192.76 (down 1.64% in 30 days). These price movements reflect broader sector trends and company-specific factors, not any impact from Ellie's Law, which is too early-stage and unfunded to affect valuations. Remaining legislative path: referral to committee (current), subcommittee review, committee markup, House floor vote, Senate companion (S1609) committee markup and floor vote, conference committee (if different versions), presidential signature, then a separate appropriations process. Even under optimistic scenarios, any tangible market impact is 2-4 years away.